Who are TRIGEL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Protonix, Xenical, Pantoprazol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trigel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TRIGEL — Competitive Intelligence Brief

TRIGEL (TRIGEL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fatty acid synthase inhibitor. Area: Cardiovascular.

marketed Fatty acid synthase inhibitor Fatty acid synthase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

TRIGEL (TRIGEL) — LobSor Pharmaceuticals AB. TRIGEL is a medication that works by lowering the levels of triglycerides in the blood.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TRIGEL TARGET	TRIGEL	LobSor Pharmaceuticals AB	marketed	Fatty acid synthase inhibitor	Fatty acid synthase
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Xenical	Xenical	Khoo Teck Puat Hospital	marketed		Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase
Pantoprazol	Pantoprazol	Northern Orthopaedic Division, Denmark	marketed		ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fatty acid synthase inhibitor class)

LobSor Pharmaceuticals AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TRIGEL — Competitive Intelligence Brief. https://druglandscape.com/ci/trigel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab